Certified by Founder Lodge
Sofinnova Investments
United States - Menlo Park, CA
INVESTOR
1 Disclosed Funding Rounds $53,000,000
7 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Since our founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade. We are a clinical-stage biopharmaceutical
| Company | Date | Round | Raised |
|---|---|---|---|
 Antiva Biosciences, Inc. |
April, 27 ,2023 | Series E | $53,000,000 |
 Quanta Therapeutics |
May, 23 ,2023 | Series D | $50,000,000 |
 Star Therapeutics |
September, 05 ,2023 | Series C | $90,000,000 |
 Aiolos Bio |
October, 26 ,2023 | Series A | $245,000,000 |
 Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
 Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
 Axonis Therapeutics |
October, 31 ,2024 | Series A | $115,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
